Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Federico Cucchiara, Iacopo Petrini, Antonio Passaro, Ilaria Attili, Stefania Crucitta, Eleonora Pardini, Filippo de Marinis, Romano Danesi, Marzia Del Re
Publikováno v:
Clinical Lung Cancer. 23:510-521
Small cell lung cancer (SCLC) is an aggressive tumor, and despite its sensitivity to chemotherapy and radiotherapy, patients usually have a short survival. There are no clinically relevant predictive factors of responses to therapies, and therapeutic
Autor:
Filippo de Marinis, Francesca Porta, Elena Guerini-Rocco, Carmine Valenza, Giuseppe Curigliano, Chiara Catania, Alessandra Rappa, Massimo Barberis, Giuseppe Viale
Publikováno v:
Current Oncology, Vol 28, Iss 292, Pp 3384-3392 (2021)
Current Oncology
Current Oncology
We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The patient then developed liver metastasis and a breast lesion, displaying high
Autor:
Paolo Tarantino, Ilaria Attili, Filippo de Marinis, Giuseppe Curigliano, Valeria Stati, Antonio Passaro
Publikováno v:
Lung Cancer. 154:151-160
The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), but most patients develop resistance to ICI treatment over time. Resistance to ICIs is mediate
Autor:
Lorenzo Spaggiari, Marina Chiara Garassino, Filippo de Marinis, Roberto Ferrara, Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Gaia Piperno, Giuseppe Lo Russo, Giulia Corrao, Roberto Orecchia, Simone Giovanni Gugliandolo
Publikováno v:
Lung Cancer. 142:70-79
Presence of liver metastases correlates with worse survival and response to any treatments. This may be due to the microenvironment of liver which leads tumor to escape from Immune System. Stereotactic Body Radiation Therapy may help to sensitize Imm
Autor:
Paolo Bidoli, Daniele Turci, Hector Soto Parra, Domenico Galetta, Fabiana Vitiello, Teresa Gamucci, Paola Antonelli, Filippo de Marinis, Giuseppe Lo Russo, Angelo Delmonte, Enrico Cortesi, Francesco Grossi, Luana Calabrò, Andrea Ardizzoni, Alessandro Morabito, Diana Giannarelli, Antonio Chella, Federico Cappuzzo, Lucio Crinò, Marcello Tiseo
Publikováno v:
The Oncologist. 24:e1165-e1171
Background Nivolumab has shown a survival benefit compared with docetaxel as second-line treatment for patients with previously treated advanced squamous non-small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients
Autor:
Filippo de Marinis, Fiona H Blackhall, Martin Früh, Dirk De Ruysscher, Cecila Le Pechoux, Mary O’ Brien, Enriqueta Felip, Silvia Novello, Sara Ramella, Paul Martin Putora, Markus Glatzer, Rafal Dziadziuszko, L. Arés, José Belderbos, Fiona McDonald, Christoph Pöttgen, Esther G.C. Troost, Ursula Nestle, Benjamin Besse, Martin Reck, Federico Cappuzzo, Joachim Widder, Raffaele Califano, Paul Van Houtte, Françoise Mornex, Virginie Westeel, Pilar Garrido, Ben J. Slotman, Stéphanie Peeters, Corinne Faivre-Finn
Publikováno v:
Putora, P M, Glatzer, M, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadziuszko, R, Felip, E, Faivre-Finn, C, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, O‘Brien, M, Paz Ares, L, Peeters, S, Pöttgen, C, Ramella, S, Reck, M, Slotman, B, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & de Ruysscher, D 2019, ' Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 133, pp. 163-166 . https://doi.org/10.1016/j.radonc.2018.12.014
Radiotherapy and Oncology, 133, 163-166. Elsevier Ireland Ltd
Radiotherapy and Oncology, 133, 163-166. Elsevier Ireland Ltd
Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Societ
Autor:
Carlo Putzu, Filippo de Marinis, Laura Bonanno, Sara Pilotto, Antonio Passaro, Lorenza Landi, Carlo Genova, Danilo Rocco, Rita Chiari, Luca Toschi, Chiara Bennati, Arsela Prelaj, Diego Cortinovis, Andrea Camerini, Marcello Tiseo, Claudia Proto, Federico Cappuzzo, Claudio Sini, Alessandro Tuzi, Giulio Cerea, Gianluca Spitaleri
Publikováno v:
Clinical Lung Cancer. 20:e186-e194
Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined predictive and druggable mutations that greatly modified patient prognoses. The most frequent driver mutations detected in NSCLC are epidermal growth factor recept
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Ester Del Signore, Francesco Petrella, Filippo de Marinis, Patrick Maisonneuve, Monica Casiraghi, Lorenzo Spaggiari, Giulia Sedda, Gaia Piperno
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objective Since data from large retrospective observational studies and cancer registries became available, suggesting a benefit for patients undergoing surgery, the role of surgery in the treatment of small cell lung cancer (SCLC) needs to be recons
Autor:
Maximilian Hochmair, A. Poltoratskiy, Michael Schumacher, Rafal Dziadziuszko, Silvia Novello, Konstantin Laktionov, Inna Egorova, Maria Rita Migliorino, Filippo de Marinis, W. Tang, Daphne Tsoi, Simona Rizzato, Gyula Ostoros, Antonio Passaro, L. Clementi, Agnieszka Cseh, Guzel Z Mukhametshina, Giulio Metro, Dariusz M. Kowalski, Maya Gottfried
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often excl